Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > This gives me less and less and less confidence

<< Previous

Bullboard Posts

Next >>

Comment by Scottyon Feb 07, 2021 6:02pm

238 Views

Post# 32497053

RE:RE:RE:RE:RE:RE:RE:RE:This gives me less and less and less confidence

I'd like to add this as well. I personally don't care how effective or revolitionary R-107 is. Salz could make a pill the cures cancer, aids, erectile disfunction, baldness, adds decades to the human life span and makes you shiit gold coins. Looking at KLY's history, there's a near 0% chance it will translate to shareholder value. We'll dilute to fund the research then find a magical way to lose the license. Fool me once.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario